Table 3.
Predictors of Viral Blips With Lamivudine-Based Dual Therapies
| Univariate Analysis | Multivariable Analysis | |||
|---|---|---|---|---|
| Variables | HR (95% CI) | P Value | aHR (95% CI) | P Value |
| M184V in hGRT | 2.51 (1.15–5.44) | .020 | 2.45 (1.09–5.53) | .030 |
| Type of DT (PI vs INI) | 0.56 (0.19–1.63) | .284 | ||
| Age (+10 y) | ||||
| Gender (male vs female) | 1.79 (0.68–4.70) | .241 | ||
| Ethnicity (Caucasian vs other) | 1.38 (0.18–10.20) | .751 | ||
| Risk factor (ref. sexual) | ||||
| IDU | 1.57 (0.53–4.68) | .420 | ||
| Other/unknown | 1.20 (0.54–3.14) | .558 | ||
| HCV infection (ref. absent) | ||||
| Present | 2.89 (1.21–6.87) | .017 | 2.71 (1.14–6.48) | .025 |
| Unknown | 1.28 (0.50–3.25) | .607 | 1.57 (0.60–4.09) | .361 |
| HBsAg (ref. negative) | ||||
| Positive | 0.00 (0.00–0.01) | .975 | ||
| Unknown | 1.17 (0.50–2.75) | .725 | ||
| Previous AIDS-defining events | 1.08 (0.38–3.13) | .883 | ||
| Time from first ART initiation (+1 y) | 1.04 (0.98–1.10) | .188 | ||
| Time of virological suppression (+1 y) | 1.02 (0.90–1.16) | .753 | ||
| Baseline CD4+ (+100 cells/µL) | 1.07 (0.95–1.21) | .233 | ||
| Nadir CD4+ (+100 cells/µL) | 0.95 (0.73–1.22) | .671 | ||
| Log zenith HIV-RNA | 1.10 (0.66–1.82) | .721 | ||
| GSS of the 2nd drug (+0.5) | 0.29 (0.08–1.56) | .113 | ||
Abbreviations: aHR, adjusted hazard ratio; ART, combined antiretroviral therapy; DT, dual therapy; GSS, genotypic sensitivity score; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; hGRT, historical genotype resistance test; HR, hazard ratio; IDU, injective drug users; INI, integrase inhibitor, PI, protease inhibitors. Significant P values (<.05) are in bold.